| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100 - 1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | T10;ADPRC 1;ADPRC1;cADPR1 |
| Entrez GeneID | 952 |
| clone | 3G8A9 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term, Avoid freeze-thaw cycles. |
| Species Reactivity | Human |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4条关于CD38抗体的参考文献摘要(基于近年研究，非真实文献，仅示例格式)：
1. **文献名称**：《CD38抗体Daratumumab在多发性骨髓瘤中的靶向治疗机制》
**作者**：Torben Plesner, et al.
**摘要**：探讨抗CD38单抗Daratumumab通过抗体依赖的细胞毒性(ADCC)和补体依赖的细胞毒性(CDC)杀伤骨髓瘤细胞，并抑制CD38酶活性调节肿瘤微环境。
2. **文献名称**：《Isatuximab联合疗法对复发/难治性多发性骨髓瘤的III期临床试验》
**作者**：Meletios A. Dimopoulos, et al.
**摘要**：研究显示，Isatuximab(抗CD38单抗)联合泊马度胺和地塞米松显著延长患者无进展生存期，证实其协同增效作用。
3. **文献名称**：《CD38表达调控与抗体耐药性机制》
**作者**：Hervé Avet-Loiseau, et al.
**摘要**：分析多发性骨髓瘤患者对CD38抗体耐药的原因，发现CD38低表达、补体抑制因子上调及免疫逃逸相关信号通路激活是关键因素。
4. **文献名称**：《CD38靶向抗体在自身免疫疾病中的潜在应用》
**作者**：Quentin Liu, et al.
**摘要**：综述CD38在调节免疫细胞(如Treg细胞、浆细胞)中的功能，提出抗CD38抗体或可治疗系统性红斑狼疮等疾病。
(注：以上文献名为模拟示例，实际文献需通过PubMed/Google Scholar等平台检索。)
CD38 is a transmembrane glycoprotein expressed on various immune cells, including plasma cells, and is notably overexpressed in multiple myeloma (MM) cells. It functions as an ectoenzyme involved in NAD+ metabolism and cell signaling, regulating processes like calcium homeostasis and immune modulation. Due to its high expression on malignant plasma cells, CD38 has emerged as a key therapeutic target in MM. Monoclonal antibodies targeting CD38. such as daratumumab and isatuximab, have revolutionized MM treatment by leveraging multiple mechanisms of action. These include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptosis induction. Additionally, CD38 antibodies modulate the immunosuppressive tumor microenvironment by depleting regulatory immune cells, enhancing anti-myeloma immune responses.
Approved by regulatory agencies since the mid-2010s, CD38 antibodies are now backbone therapies in MM, used as monotherapy or in combination with immunomodulatory drugs, proteasome inhibitors, or corticosteroids. Their efficacy extends to relapsed/refractory cases and newly diagnosed patients, significantly improving progression-free and overall survival. Beyond MM, CD38-targeting agents are being explored in other hematologic malignancies and autoimmune disorders. However, challenges like resistance mechanisms and treatment-related immunosuppression (e.g., increased infection risk) persist. Ongoing research focuses on optimizing dosing, combination strategies, and next-generation anti-CD38 therapies (e.g., bispecific antibodies or antibody-drug conjugates) to address unmet needs in MM management.
×
